Top

Clinical and Translational Oncology

Published in:

01-12-2012 | Research Article

Characteristics and long-term survival of colorectal cancer patients aged 44 years and younger

Authors: Zuli Yang, Liang Kang, Lei Wang, Jun Xiang, Guanfu Cai, Ji Cui, Junsheng Peng, Ping Lan, Jianping Wang

Published in: Clinical and Translational Oncology | Issue 12/2012

Abstract

Background

This study was to investigate the clinicopathologic characteristics and prognosis of colorectal cancer (CRC) patients aged 44 years and younger.

Methods

Patients were identified from a prospectively maintained CRC database and divided into two groups by age: younger and older group (≤44 and >44 years). Clinicopathologic characteristics and postoperative outcomes were compared.

Results

There were 530 patients aged ≤44 years at diagnosis. More patients in the younger group had a family history of CRC compared with older patients. Younger patients were more likely than older patients to have larger tumours, infiltrative growth type tumours, poorly differentiated tumours, mucinous and signet-ring cell adenocarcinoma, and advanced TNM stages. Compared to older patients, more younger patients received chemotherapy and died of cancer-related causes. Overall survival, disease-free survival and cancer-specific survival of younger patients were comparable to older patients. Blood transfusion, TNM stage, histological grade and disease recurrence were independently associated with survival in the younger group.

Conclusions

Despite younger patients having unfavourable clinicopathologic features, younger age at diagnosis of CRC appears to be associated with similar oncologic outcomes as compared to older patients.

Zhao P, Dai M, Chen W et al (2010) Cancer trends in China. Jpn J Clin Oncol 40(4):281–285PubMedCrossRef

Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef

Center MM, Jemal A, Smith RA et al (2009) Worldwide variations in colorectal cancer. CA Cancer J Clin 59:366–378PubMedCrossRef

Cao KJ, Ma GS, Liu YL et al (2009) Incidence of colorectal cancer in Guangzhou City from 2000 to 2002. Chin J Cancer 28:441–444

An-Gao Xu, Zhi-Jin Yu, Jiang Bo et al (2010) Colorectal cancer in Guangdong Province of China: a demographic and anatomic survey. World J Gastroenterol 16(8):960–965CrossRef

O’Connell JB, Maggard MA, Livingston EH et al (2004) Colorectal cancer in the young. Am J Surg 187:343–348PubMedCrossRef

Karsten B, Kim J, King J et al (2008) Characteristics of colorectal cancer in young patients at an urban county hospital. Am Surg 74:973–976PubMed

Fairley TL, Cardinez CJ, Martin J et al (2006) Colorectal cancer in US Adults young than 50 years of age, 1998–2001. Cancer 107:1153–1161PubMedCrossRef

Surveillance, Epidemiology, and End Results (SEER) Program (2002) Public-use data (1973–1999). Cancer Statistics Branch, Surveillance Research Program, DCCPS. http://www.seer.cancer.gov

10.

Soliman AS, Bondy ML, Levin B et al (1997) Colorectal cancer in Egyptian patients under 40 years of age. Int J Cancer 71(1):26–30PubMedCrossRef

11.

Marble K, Banerjee S, Greenwald L (1992) Colorectal carcinoma in young patients. J Surg Oncol 51(3):179–182PubMedCrossRef

12.

Liang JT, Huang KC, Cheng AL et al (2003) Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age. Br J Surg 90:205–214PubMedCrossRef

13.

Chiang JM, Chen MC, Changchien CR et al (2003) Favorable influence of age on tumor characteristics of sporadic colorectal adenocarcinoma: patients 30 years of age or younger may be a distinct patient group. Dis Colon Rectum 46(7):904–910PubMedCrossRef

14.

Leff DR, Chen A, Roberts D et al (2007) Colorectal cancer in the young patient. Am Surg 73(1):42–47PubMed

15.

O’Connell JB, Maggard MA, Liu JH et al (2003) Rates of colon and rectal cancers are increasing in young adults. Am Surg 69(10):866–872PubMed

16.

Mitry E, Benhamiche AM, Jouve JL et al (2001) Colorectal adenocarcinoma in patients under 45 years of age: comparison with older patients in a well-defined French population. Dis Colon Rectum 44(3):380–387PubMedCrossRef

17.

Quah HM, Joseph R, Schrag D et al (2007) Young age influences treatment but not outcome of colon cancer. Ann Surg Oncol 14(10):2759–2765PubMedCrossRef

18.

Vasen HF, Watson P, Mecklin JP et al (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116(6):1453–1456PubMedCrossRef

19.

O’Connell JB, Maggard MA, Liu JH et al (2004) Are survival rates different for young and older patients with rectal cancer? Dis Colon Rectum 47(12):2064–2069PubMedCrossRef

20.

Shemesh-Bar L, Kundel Y, Idelevich E et al (2010) Colorectal cancer in young patients in Israel: a distinct clinicopathological entity? World J Surg 34(11):2701–2709PubMedCrossRef

21.

Keating J, Yong D, Cutler G et al (2006) Multidisciplinary treatment of colorectal cancer in New Zealand: survival rates from 1997–2002. N Z Med J 119(1242):U2238PubMed

22.

Alici S, Aykan NF, Sakar B et al (2003) Colorectal cancer in young patients: characteristics and outcome. Tohoku J Exp Med 199(2):85–93PubMedCrossRef

23.

Kam MH, Eu KW, Barben CP et al (2004) Colorectal cancer in the young: a 12-year review of patients 30 years or less. Colorectal Dis 6(3):191–194PubMedCrossRef

24.

Frizis H, Papadopoulos A, Akritidis G et al (2004) Are there any differences in colorectal cancer between young and elderly patients? Tech Coloproctol 8(Suppl 1):s147–s148PubMedCrossRef

25.

Günel N, Yamac D, Akcali Z et al (2001) The clinicopathologic characteristics of colorectal cancer in patients under 50 years of age: experience of an oncology center. Tumori 87(2):74–77PubMed

26.

Chu DZ, Lang NP, Thompson C et al (1989) Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 63(2):364–367PubMedCrossRef

27.

Tominaga T, Sakabe T, Koyama Y et al (1996) Prognostic factors for patients with colon or rectal carcinoma treated with resection only. Five-year follow-up report. Cancer 78(3):403–408PubMedCrossRef

28.

Sadahiro S, Suzuki T, Ishikawa K et al (2003) Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years. Hepatogastroenterology 50(53):1362–1366PubMed

29.

Manfredi S, Lepage C, Hatem C et al (2006) Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244(2):254–259PubMedCrossRef

30.

Chew MH, Koh PK, Ng KH et al (2009) Improved survival in an Asian cohort of young colorectal cancer patients: an analysis of 523 patients from a single institution. Int J Colorectal Dis 24(9):1075–1083PubMedCrossRef

31.

Endreseth BH, Romundstad P, Myrvold HE, Norwegian Rectal Cancer Group et al (2006) Rectal cancer in the young patient. Dis Colon Rectum 49(7):993–1001PubMedCrossRef

32.

Paraf F, Jothy S (2000) Colorectal cancer before the age of 40: a case–control study. Dis Colon Rectum 43(9):1222–1226PubMedCrossRef

33.

Smith C, Butler JA (1989) Colorectal cancer in patients younger than 40 years of age. Dis Colon Rectum 2(10):43–46

34.

Liang H, Wang XN, Wang BG et al (2006) Prognostic factors of young patients with colon cancer after surgery. World J Gastroenterol 2(9):458–462

35.

Nilsson KR, Berenholtz SM, Dorman T et al (2002) Preoperative predictors of blood transfusion in colorectal cancer surgery. J Gastrointest Surg 6(5):753–762PubMedCrossRef

Title: Characteristics and long-term survival of colorectal cancer patients aged 44 years and younger
Authors: Zuli Yang
Liang Kang
Lei Wang
Jun Xiang
Guanfu Cai
Ji Cui
Junsheng Peng
Ping Lan
Jianping Wang
Publication date: 01-12-2012
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 12/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0876-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2012

Functional and biologic metrics for predicting radiation pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy

Intraperitoneal bevacizumab combined with cytoreductive surgery: a pre-clinical study of tolerance and pharmacokinetics in an animal model

Comments on “SEOM guidelines for endometrial cancer”

Conservative surgery, external radiotherapy, and HDR brachytherapy in a single fraction of 7 Gy in early breast cancer: long-term toxicity and esthetic assessment

Therapeutic nanosystems for oncology nanomedicine

Clinical importance of phosphatase of regenerating liver-3 expression in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer